<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35482908</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>RNA biology</Title><ISOAbbreviation>RNA Biol</ISOAbbreviation></Journal><ArticleTitle>Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.</ArticleTitle><Pagination><StartPage>594</StartPage><EndPage>608</EndPage><MedlinePgn>594-608</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15476286.2022.2066334</ELocationID><Abstract><AbstractText>RNA therapeutics comprise a diverse group of oligonucleotide-based drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) that can be designed to selectively interact with drug targets currently undruggable with small molecule-based drugs or monoclonal antibodies. Furthermore, RNA-based therapeutics have the potential to modulate entire disease pathways, and thereby represent a new modality with unprecedented potential for generating disease-modifying drugs for a wide variety of human diseases, including central nervous system (CNS) disorders. Here, we describe different strategies for delivering RNA drugs to the CNS and review recent advances in clinical development of ASO drugs and siRNA-based therapeutics for the treatment of neurological diseases and neuromuscular disorders.<b>Abbreviations</b> 2'-MOE: 2'-<i>O</i>-(2-methoxyethyl); 2'-<i>O</i>-Me: 2'-<i>O</i>-methyl; 2'-F: 2'-fluoro; AD: Alzheimer's disease; ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; ARC: Antibody siRNA Conjugate; AS: Angelman Syndrome; ASGRP: Asialoglycoprotein receptor; ASO: Antisense oligonucleotide; AxD: Alexander Disease; BBB: Blood brain barrier; Bp: Basepair; CNM: Centronuclear myopathies; CNS: Central Nervous System; CPP: Cell-penetrating Peptide; CSF: Cerebrospinal fluid; DMD: Duchenne muscular dystrophy; DNA: Deoxyribonucleic acid; FAP: Familial amyloid polyneuropathy; FALS: Familial amyotrophic lateral sclerosis; FDA: The United States Food and Drug Administration; GalNAc: N-acetylgalactosamine; GoF: Gain of function; hATTR: Hereditary transthyretin amyloidosis; HD: Huntington's disease; HRQOL: health-related quality of life; ICV: Intracerebroventricular; IT: Intrathecal; LNA: Locked nucleic acid; LoF: Loss of function; mRNA: Messenger RNA; MS: Multiple Sclerosis; MSA: Multiple System Atrophy; NBE: New Biological Entity; NCE: New Chemical Entity; NHP: Nonhuman primate; nt: Nucleotide; PD: Parkinson's disease; PNP: Polyneuropathy; PNS: Peripheral nervous system; PS: Phosphorothioate; RISC: RNA-Induced Silencing Complex; RNA: Ribonucleic acid; RNAi: RNA interference; s.c.: Subcutaneous; siRNA: Small interfering RNA; SMA: Spinal muscular atrophy; SMN: Survival motor neuron; TTR: Transthyretin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, A.C. Meyers V&#xe6;nge 15, 2450 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Stine N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Neumirna Therapeutics, A.C. Meyers V&#xe6;nge 15, 2450 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klitgaard</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neumirna Therapeutics, A.C. Meyers V&#xe6;nge 15, 2450 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauppinen</LastName><ForeName>Sakari</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, A.C. Meyers V&#xe6;nge 15, 2450 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>RNA Biol</MedlineTA><NlmUniqueID>101235328</NlmUniqueID><ISSNLinking>1547-6286</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C567782">Amyloidosis, Hereditary, Transthyretin-Related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D028227" MajorTopicYN="N">Amyloid Neuropathies, Familial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="Y">Neuromuscular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CNS</Keyword><Keyword MajorTopicYN="N">RNA-based therapeutics</Keyword><Keyword MajorTopicYN="N">Small interfering RNA</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">gene silencing</Keyword><Keyword MajorTopicYN="N">neurological disease</Keyword><Keyword MajorTopicYN="N">neuromuscular disorder</Keyword></KeywordList><CoiStatement>S.N.H. is an employee and H.K. and S.K. are scientific cofounders of Neumirna Therapeutics, a biopharmaceutical company developing RNA-based therapeutics for neurological disorders and have shares in the company. A.H. declares no competing interests. The figures were created with BioRender.com.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>14</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35482908</ArticleId><ArticleId IdType="pmc">PMC9067473</ArticleId><ArticleId IdType="doi">10.1080/15476286.2022.2066334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roberts E, Frankel S.. Gamma-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem. 1950;187:55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14794689</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson A. Thirty years of dopamine research. Adv Neurol. 1993;60:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093570</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett. 2010;486 :107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433163</ArticleId><ArticleId IdType="pubmed">20816922</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH. Anti-amyloid-beta; monoclonal antibodies for Alzheimer&#x2019;s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767539</ArticleId><ArticleId IdType="pubmed">28967385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaikath NN, Hmila I, Gupta V, et al. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">31055836</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen TL, G&#xf8;tzsche CR, Woldbye DPD. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Front Mol Neurosci. 2021;14:695937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527017</ArticleId><ArticleId IdType="pubmed">34690692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajan S, Hutvagner G. RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells. 2020;9:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016530</ArticleId><ArticleId IdType="pubmed">31936122</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics &#x2014; challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212082</ArticleId><ArticleId IdType="pubmed">34145432</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35:230&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244996</ArticleId></ArticleIdList></Reference><Reference><Citation>Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35:238&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517098</ArticleId><ArticleId IdType="pubmed">28244990</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">25353652</ArticleId></ArticleIdList></Reference><Reference><Citation>Vester B, Wengel J. LNA (Locked Nucleic Acid): high-affinity targeting of complementary RNA and DNA. Biochemistry. 2004;43:13233&#x2013;13241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491130</ArticleId></ArticleIdList></Reference><Reference><Citation>Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212909</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid. Biochim Biophys Acta. 1999;1489:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807005</ArticleId></ArticleIdList></Reference><Reference><Citation>Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol. 2005;5:550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087398</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon BM, Mays D, Lipsky J, et al. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 2002;12:65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074366</ArticleId></ArticleIdList></Reference><Reference><Citation>Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">9486653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2:711&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097247</ArticleId><ArticleId IdType="pubmed">17108989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcan G, Ozpolat B, Coleman RL, et al. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504743</ArticleId><ArticleId IdType="pubmed">25666164</ArticleId></ArticleIdList></Reference><Reference><Citation>Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675692</ArticleId><ArticleId IdType="pubmed">19239886</ArticleId></ArticleIdList></Reference><Reference><Citation>Choung S, Kim YJ, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342:919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16598842</ArticleId></ArticleIdList></Reference><Reference><Citation>Judge AD, Bola G, Lee ACH, et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13:494&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16343994</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoharan M, Akinc A, Pandey RK, et al. Unique gene-silencing and structural properties of 2&#x2032;-fluoro-modified siRNAs. Angew Chem Int Educ. 2011;50:2284&#x2013;2288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516925</ArticleId><ArticleId IdType="pubmed">21351337</ArticleId></ArticleIdList></Reference><Reference><Citation>Allerson CR, Sioufi N, Jarres R, et al. Fully 2&#x2018;-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48:901&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715458</ArticleId></ArticleIdList></Reference><Reference><Citation>Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003;13:83&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12804036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima WF, Prakash T, Murray H, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150:883&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">22939618</ArticleId></ArticleIdList></Reference><Reference><Citation>Haraszti RA, Roux L, Coles AH, et al. 5&#x384;-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 2017;45:7581&#x2013;7592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570069</ArticleId><ArticleId IdType="pubmed">28591791</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlegel MK, Foster DJ, Kel&#x2019;in AV, et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc. 2017;139:8537&#x2013;8546.</Citation><ArticleIdList><ArticleId IdType="pubmed">28570818</ArticleId></ArticleIdList></Reference><Reference><Citation>Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818625</ArticleId><ArticleId IdType="pubmed">29459660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM. Blood&#x2013;brain barrier delivery. Drug Discov Today. 2007;12:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17198973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hach&#xe9; M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31:899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871174</ArticleId><ArticleId IdType="pubmed">26823478</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordts I, Lingor P, Friedrich B, et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974755</ArticleId><ArticleId IdType="pubmed">32010224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolani S, Stura G, Ventilii G, et al. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach. Neuromuscul Disord. 2019;29:742&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">31604650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascene DR, Ozutemiz C, Estby H, et al. Transforaminal lumbar puncture: an alternative technique in patients with challenging access. Am J Neuroradiol. 2018;39:986&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410647</ArticleId><ArticleId IdType="pubmed">29567652</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss KA, Carson VJ, Brigatti KW, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop. 2018;38 e610&#x2013;617. DOI:10.1097/BPO.0000000000001247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BPO.0000000000001247</ArticleId><ArticleId IdType="pmc">PMC6211782</ArticleId><ArticleId IdType="pubmed">30134351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazorthes Y, Sallerin-Caute B, Verdie J-C, et al. Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg. 1990;72:393&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">2303874</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation: Technology at the Neural Interface. 2017;20(2):96&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">28042904</ArticleId></ArticleIdList></Reference><Reference><Citation>Draulans N, Vermeersch K, Degraeuwe B, et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil. 2013;27:1137&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">23858524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafar-nejad P, Powers B, Soriano A, et al. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res. 2021;49:657&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826274</ArticleId><ArticleId IdType="pubmed">33367834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Mateos EM, Engel T, Merino-Serrais P, et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med. 2012;18:1087&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438344</ArticleId><ArticleId IdType="pubmed">22683779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol. 2017;67:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28089765</ArticleId></ArticleIdList></Reference><Reference><Citation>uniQure, Press Release. Accessed 15
Dec 2021
http://www.uniqure.com/patients/phase-1-2-clinical-trial-of-amt-130.php. .</Citation></Reference><Reference><Citation>Padmakumar S, Jones G, Pawar G, et al. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J Control Release. 2021;331:176&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946770</ArticleId><ArticleId IdType="pubmed">33484777</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A, Huang Y, Querbes W, et al. Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J Control Release. 2012;163:125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010143</ArticleId><ArticleId IdType="pubmed">22921802</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Lee H, Fang Z, et al. Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles. Sci Adv. 2021;7:eabf7390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087400</ArticleId><ArticleId IdType="pubmed">33931452</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinho BMDC, Henninger N, Bouley J, et al. Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier. Mol Ther. 2018;26:2580&#x2013;2591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225091</ArticleId><ArticleId IdType="pubmed">30143435</ArticleId></ArticleIdList></Reference><Reference><Citation>Reschke CR, Silva LFA, Vangoor VR, et al. Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy. Mol Ther. 2021;29:2041&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8178478</ArticleId><ArticleId IdType="pubmed">33609732</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5:209ra152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017940</ArticleId><ArticleId IdType="pubmed">24174328</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeniya S, Kuwahara H, Daizo K, et al. Angubindin-1 opens the blood&#x2013;brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. J Control Release. 2018;283:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">29753959</ArticleId></ArticleIdList></Reference><Reference><Citation>Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability in Parkinson&#x2019;s disease: an update. Front Neuroanat. 2014;8:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266033</ArticleId><ArticleId IdType="pubmed">25565977</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol. 2016;524:3865&#x2013;3895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063692</ArticleId><ArticleId IdType="pubmed">27187682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vocelle D, Chan C, Walton SP. Endocytosis controls siRNA efficiency: implications for siRNA delivery vehicle design and cell-specific targeting. Nucleic Acid Ther. 2019;30:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6987736</ArticleId><ArticleId IdType="pubmed">31718426</ArticleId></ArticleIdList></Reference><Reference><Citation>Deprey K, Batistatou N, Kritzer JA. A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics. Nucleic Acids Res. 2020;48:7623&#x2013;7639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430645</ArticleId><ArticleId IdType="pubmed">32644123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair JK, Willoughby JLS, Chan A, et al. Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. J Am Chem Soc. 2014;136:16958&#x2013;16961.</Citation><ArticleIdList><ArticleId IdType="pubmed">25434769</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YY. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363494</ArticleId><ArticleId IdType="pubmed">28325278</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci. 2007;104:17204&#x2013;17209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040405</ArticleId><ArticleId IdType="pubmed">17940007</ArticleId></ArticleIdList></Reference><Reference><Citation>Alterman JF, Hall LM, Coles AH, et al. Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids. 2015;4:e266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014532</ArticleId><ArticleId IdType="pubmed">26623938</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016;20:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27986223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond SM, Abendroth F, Goli L, et al. Systemic antibody-oligonucleotide delivery to the central nervous system ameliorates mouse models of spinal muscular atrophy. bioRxiv. 2021. .July.29; 454272. DOI:10.1101/2021.07.29.454272</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.29.454272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W, Gao X. Functional peptides for siRNA delivery. Adv Drug Deliv Rev. 2017;110&#x2013;111:157&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305781</ArticleId><ArticleId IdType="pubmed">27530388</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabanpoor F, Hammond SM, Abendroth F, et al. Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther. 2017;27:130&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467147</ArticleId><ArticleId IdType="pubmed">28118087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Patiyal S, Kumar R, et al. B3Pdb: an archive of blood&#x2013;brain barrier-penetrating peptides. Brain Struct Funct. 2021;226:2489&#x2013;2495.</Citation><ArticleIdList><ArticleId IdType="pubmed">34269889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75:193&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756260</ArticleId><ArticleId IdType="pubmed">28733901</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurung S, Perocheau D, Touramanidou L, et al. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021;19:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063428</ArticleId><ArticleId IdType="pubmed">33892745</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">21423189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JM, Wiklander PBO, Nordin JZ, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014;29:1476&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204174</ArticleId><ArticleId IdType="pubmed">25112864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhang X, Chen X, et al. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Ther Nucleic Acids. 2017;7:278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5415550</ArticleId><ArticleId IdType="pubmed">28624203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui G, Guo H-D, Li H, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer&#x2019;s disease. Immun Ageing. 2019;16:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6515654</ArticleId><ArticleId IdType="pubmed">31114624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Badawi M, Pomeroy S, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles. 2017;6:1324730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505007</ArticleId><ArticleId IdType="pubmed">28717420</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan X, Sansanaphongpricha K, Myers I, et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38:754&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520184</ArticleId><ArticleId IdType="pubmed">28392567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles&#x2014;from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982&#x2013;17015.</Citation><ArticleIdList><ArticleId IdType="pubmed">34181394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirunagi T, Sahashi K, Tachikawa K, et al. Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS. Mol Ther Nucleic Acids. 2021;24:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937577</ArticleId><ArticleId IdType="pubmed">33738134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rungta RL, Choi HB, Lin PJ, et al. Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids. 2013;2:e136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889191</ArticleId><ArticleId IdType="pubmed">24301867</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglut CT, Sorrin AJ, Kuruppu T, et al. Immunological and toxicological considerations for the design of liposomes. Nanomaterials. 2020;10:190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074910</ArticleId><ArticleId IdType="pubmed">31978968</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">23984729</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnaby SN, Sita TL, Petrosko SH. et al. Therapeutic applications of spherical nucleic acids . Nanotechnology-based precision tools for the detection and treatment of cancer. eds. Mirkin CA, Meade TJ, Petrosko SH, et al. Switzerland: Springer International Publishing. 2015;23&#x2013;50. DOI:10.1007/978-3-319-16555-4_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-16555-4_2</ArticleId><ArticleId IdType="pubmed">25895863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sita TL, Kouri FM, Hurley LA, et al. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc Natl Acad Sci. 2017;114:4129&#x2013;4134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5402467</ArticleId><ArticleId IdType="pubmed">28373576</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Xia Q, Wang P. Rationally designed DNA nanostructures for drug delivery. Front Chem. 2020;8:751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542244</ArticleId><ArticleId IdType="pubmed">33195016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam DY, Weng-Thim Ho J, Chan MS, et al. Penetrating the blood&#x2013;brain barrier by self-assembled 3D DNA nanocages as drug delivery vehicles for brain cancer therapy. ACS Appl Mater Interfaces. 2020;12:28928&#x2013;28940.</Citation><ArticleIdList><ArticleId IdType="pubmed">32432847</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Accessed 15
Dec 2021. https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza&#xae;-&#x2013;-Spinal-Muscular</Citation></Reference><Reference><Citation>NIH. Accessed 15
Dec 2021. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet</Citation></Reference><Reference><Citation>Biogen. Press Release. Accessed 05
Apr 2022. https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results</Citation></Reference><Reference><Citation>Ionis. Accessed 15
Dec 2021. https://www.ionispharma.com/ionis-innovation/pipeline/</Citation></Reference><Reference><Citation>Habtemariam BA, Karsten V, Attarwala H, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine&#x2013;small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109:372&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">32599652</ArticleId></ArticleIdList></Reference><Reference><Citation>Alnylam. Accessed 15
Dec 2021. https://www.businesswire.com/news/home/20210107005224/en/Alnylam-Reports-Positive-Topline-Results-from-HELIOS-A-Phase-3-Study-of-Vutrisiran-in-Patients-with-hATTR-Amyloidosis-with-Polyneuropathy</Citation></Reference><Reference><Citation>Holm A, L&#xf8;vendorf MB, Kauppinen S. Development of siRNA therapeutics for the treatment of liver diseases. In: Ditzel HJ, Tuttolomondo M, Kauppinen S, editors. Design and delivery of siRNA therapeutics. New York, NY, USA: Humana; 2021. p. 57&#x2013;75. DOI:10.1007/978-1-0716-1298-9_5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1298-9_5</ArticleId><ArticleId IdType="pubmed">33928570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionis. Accessed 15
Dec 2021. https://www.ionispharma.com/medicines/akcea-ttr-l/</Citation></Reference><Reference><Citation>Huntington's Disease Society of America. Accessed 19
Apr 2022. https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/</Citation></Reference><Reference><Citation>Ionis. Accessed 15
Dec 2021. https://www.ionispharma.com/medicines/ionis-htt/</Citation></Reference><Reference><Citation>Roche. Accessed 15
Dec 2021. https://www.roche.com/de/media/releases/med-cor-2021-03-22b.htm</Citation></Reference><Reference><Citation>Kingwell K. Double setback for ASO trials in Huntington disease. Nat Rev Drug Discov. 2021;20:412&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">34012000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann TL. Alexander disease: models, mechanisms, and medicine. Curr Opin Neurobiol. 2022;72:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901527</ArticleId><ArticleId IdType="pubmed">34826654</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04849741</Citation></Reference><Reference><Citation>Angelman Syndrome Foundation. Accessed 15
Dec 2021. https://www.angelman.org/for-parents/angelman-therapies/</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04428281</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04259281?term=GTX-102&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>National Organization for Rare Disorders. Accessed 15
Dec 2021. https://rarediseases.org/rare-diseases/centronuclear-myopathy/</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04033159?term=NCT04033159&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>MayoClinic. Accessed 15
Dec 2021. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT03186989?term=NCT03186989&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson&#x2019;s disease: three questions. ASN Neuro. 2009;1:e00002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695577</ArticleId><ArticleId IdType="pubmed">19570025</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT03976349?term=NCT03976349&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>NHS. Accessed 15
Dec 2021. https://www.nhs.uk/conditions/multiple-system-atrophy/</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04165486?term=BIIB101&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.</Citation><ArticleIdList><ArticleId IdType="pubmed">30410033</ArticleId></ArticleIdList></Reference><Reference><Citation>Limmroth V, Barkhof F, Desem N, et al. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology. 2014;83:1780&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240428</ArticleId><ArticleId IdType="pubmed">25239835</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmuely S, Sisodiya SM, Gunning WB, et al. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732919</ArticleId></ArticleIdList></Reference><Reference><Citation>Dravet Syndrome News. Accessed 15
Dec 2021. https://dravetsyndromenews.com/2020/12/08/fda-allows-higher-dose-stk-001-for-adolescents-children-with-dravet-syndrome-in-monarch-trial/</Citation></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04740476</Citation></Reference><Reference><Citation>Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017&#x2013;3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS
Accessed 15
Dec 2021. https://www.nhs.uk/conditions/muscular-dystrophy/</Citation></Reference><Reference><Citation>Angelini G, Mura G, Messina G. Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: the importance of the secondary therapies. Exp Cell Res. 2022;410:112968.</Citation><ArticleIdList><ArticleId IdType="pubmed">34883113</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarepta. Accessed 15
Dec 2021. https://www.sarepta.com/products-pipeline/pipeline</Citation></Reference><Reference><Citation>Stein CA. Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice. Mol Ther. 2016;24:1884&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154484</ArticleId><ArticleId IdType="pubmed">27916994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338848</ArticleId><ArticleId IdType="pubmed">28280301</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29972757</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam SJ. Inotersen: first global approval. Drugs. 2018;78:1371&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">30120737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu RZ, Collins JW, Hall S, et al. Population pharmacokinetic&#x2013;pharmacodynamic modeling of inotersen, an antisense oligonucleotide for treatment of patients with hereditary transthyretin amyloidosis. Nucleic Acid Ther. 2020;30:153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249474</ArticleId><ArticleId IdType="pubmed">32286934</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials. Accessed 15
Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04136184?term=eplontersen&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Zlatev I, Castoreno A, Brown CR, et al. Reversal of siRNA-mediated gene silencing in vivo. Nat Biotechnol. 2018;36:509&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">29786096</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby JR, Zhao C, Zhang H, et al. Reversing antisense oligonucleotide activity with a sense oligonucleotide antidote: proof of concept targeting prothrombin. Nucleic Acid Ther. 2015;25:297&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">26390010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>